Evidence map›Paper›PMID 33880737›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021

Restless Legs Syndrome: Contemporary Diagnosis and Treatment.

Thomas R Gossard, Lynn Marie Trotti, Aleksandar Videnovic, Erik K St Louis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Restless Legs Syndrome in Chronic Kidney Disease- a Systematic Review.Tremor and other hyperkinetic movements (New York, N.Y.) · 2023
    Pooled it
  12. Putative Animal Models of Restless Legs Syndrome: A Systematic Review and Evaluation of Their Face and Construct Validity.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas R GossardMayo Center for Sleep Medicine, 200 First Street SW, Rochester, MN, 55905, USA.
Lynn Marie TrottiEmory University, Atlanta, GA, USA.
Aleksandar VidenovicMassachusetts General Hospital, Boston, MA, USA.
Erik K St LouisMayo Center for Sleep Medicine, 200 First Street SW, Rochester, MN, 55905, USA. StLouis.Erik@mayo.edu.ORCID http://orcid.org/0000-0002-2833-8826

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS)UL1TR002377 · MAYO CLINIC ROCHESTER · 2025 to 2025
$7.2M
NCATS NIH HHS UL1 TR002377NIA NIH HHS R34AG056639
6 · The paper itself

Abstract

Restless legs syndrome (RLS) is characterized by an uncomfortable urge to move the legs while at rest, relief upon movement or getting up to walk, and worsened symptom severity at night. RLS may be primary (idiopathic) or secondary to pregnancy or a variety of systemic disorders, especially iron deficiency, and chronic renal insufficiency. Genetic predisposition with a family history is common. The pathogenesis of RLS remains unclear but is likely to involve central nervous system dopaminergic dysfunction, as well as other, undefined contributing mechanisms. Evaluation begins with a thorough history and examination, and iron measures, including ferritin and transferrin saturation, should be checked at presentation and with worsened symptoms, especially when augmentation develops. Augmentation is characterized by more intense symptom severity, earlier symptom occurrence, and often, symptom spread from the legs to the arms or other body regions. Some people with RLS have adequate symptom control with non-pharmacological measures such as massage or temperate baths. First-line management options include iron-replacement therapy in those with evidence for reduced body-iron stores or, alternatively, with prescribed gabapentin or pregabalin, and dopamine agonists such as pramipexole, ropinirole, and rotigotine. Second-line therapies include intravenous iron infusion in those who are intolerant of oral iron and/or those having augmentation with intense, severe RLS symptoms, and opioids including tramadol, oxycodone, and methadone. RLS significantly impacts patients' quality of life and remains a therapeutic area sorely in need of innovation and a further pipeline of new, biologically informed therapies.

Indexed as

Quality of LifeDopamine AgonistsHumansRestless Legs SyndromeDopamine AgonistsAlpha-2-delta ligandCardiovascular riskDopamine agonistIron deficiency.OpiatePeriodic leg movementsPeriodic limb movement disorderRestless legs syndromeTreatment

Identifiers

PMID33880737
PMCPMC8116476

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.